Purple Biotech Ltd (PPBT) - Total Assets
Based on the latest financial reports, Purple Biotech Ltd (PPBT) holds total assets worth ILA39.06 Million ILA (≈ $104.72K USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Purple Biotech Ltd - Total Assets Trend (2017–2024)
This chart illustrates how Purple Biotech Ltd's total assets have evolved over time, based on quarterly financial data. Also see Purple Biotech Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Purple Biotech Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Purple Biotech Ltd's total assets of ILA39.06 Million consist of 24.1% current assets and 76.0% non-current assets. Review PPBT total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 20.0% |
| Accounts Receivable | ILA0.00 | 0.0% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA27.84 Million | 75.2% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Purple Biotech Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Purple Biotech Ltd (PPBT) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Purple Biotech Ltd's current assets represent 24.1% of total assets in 2024, a decrease from 56.3% in 2017.
- Cash Position: Cash and equivalents constituted 20.0% of total assets in 2024, down from 27.8% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 75.0% of total assets, an increase from 43.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 75.2% of total assets.
Purple Biotech Ltd Competitors by Total Assets
Key competitors of Purple Biotech Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Purple Biotech Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.78 | 1.27 | 19.14 |
| Quick Ratio | 1.78 | 1.27 | 19.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA4.72 Million | ILA1.48 Million | ILA56.18 Million |
Purple Biotech Ltd - Advanced Valuation Insights
This section examines the relationship between Purple Biotech Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.24 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -16.4% |
| Total Assets | ILA37.04 Million |
| Market Capitalization | $4.84 Million USD |
Valuation Analysis
Below Book Valuation: The market values Purple Biotech Ltd's assets below their book value (0.13x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Purple Biotech Ltd's assets decreased by 16.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Purple Biotech Ltd (2017–2024)
The table below shows the annual total assets of Purple Biotech Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ILA37.04 Million ≈ $99.30K |
-16.40% |
| 2023-12-31 | ILA44.30 Million ≈ $118.77K |
-18.89% |
| 2022-12-31 | ILA54.62 Million ≈ $146.44K |
-22.19% |
| 2021-12-31 | ILA70.20 Million ≈ $188.20K |
-16.23% |
| 2020-12-31 | ILA83.80 Million ≈ $224.67K |
+469.39% |
| 2019-12-31 | ILA14.72 Million ≈ $39.46K |
-0.03% |
| 2018-12-31 | ILA14.72 Million ≈ $39.47K |
+3.81% |
| 2017-12-31 | ILA14.18 Million ≈ $38.02K |
-- |
About Purple Biotech Ltd
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, whi… Read more